Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery
Yale University
700 participants
Jan 28, 2020
INTERVENTIONAL
Conditions
Summary
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Apixaban is an oral anticoagulant of the Factor Xa inhibitor class.
Aspirin is an oral antiplatelet drug.
Locations(184)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03907046